WEIGHT: 50 kg
Services: Pole Dancing, Hand Relief, Receiving Oral, Naturism/Nudism, TOY PLAY
Search Filters. Trial Filters. A listing of Tuzla, Bosnia and Herzegovina clinical trials actively recruiting patients volunteers. The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil PSL administered concomitantly with up to 3 anti-epileptic drugs AEDs compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy. Patients who meet criteria for participation in this study receive 8 intravenous infusions of MabionCD20 or MabThera 21 days interval in combination with standard dosage regimen of CHOP.
The duration of the study is 12 months. The treatment and observation period will last 26 weeks starting from Day 1, until This will be a randomized, double-blind, active- and placebo-controlled, parallel-group study in subjects with clinically active RA but who are MTX-nave.
Subjects who meet enrollment criteria will be randomized to 1 of 4 groups in a ratio: CF 1 mg, CF 2 mg, MTX, or matching placebo tablets. The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a Avonex , once a week intramuscularly in participants with RMS.
The objective of this study is to evaluate the efficacy and safety of Upadacitinib compared to placebo in inducing clinical remission per Adapted Mayo score in participants with moderately to severely active ulcerative colitis UC.
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.